• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 2020 年 1 月至 2021 年 2 月收集的数据,分析 SARS-CoV-2 在武汉、中国其他地区和全球的流行病学特征。

Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021.

机构信息

Department of Laboratory and Quarantine, Dalian Medical University, Dalian, China.

出版信息

Medicine (Baltimore). 2022 Aug 12;101(32):e30019. doi: 10.1097/MD.0000000000030019.

DOI:10.1097/MD.0000000000030019
PMID:35960106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9370246/
Abstract

This observation study examines coronavirus disease 2019 (COVID-19) data from outbreak and other sites in China and worldwide in order to examine the epidemiological pattern of COVID-19 before the acquisition of immunity through widespread vaccination and infection. COVID-19-related morbidity and mortality data for January 2020 to February 2021 were obtained from the Chinese Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, and the World Health Organization. The number of cases was logarithmically transformed for comparison of the rate of increase or decrease with time across areas. From January to February 2020, the number of new confirmed cases in Wuhan grew substantially but returned to zero by May 2020. In other parts of China, the rate of decrease was lower than that in Wuhan, and the mortality rate was lower outside Wuhan (1.93%) than in Wuhan (7.68%). The influenza trends were similar to those of COVID-19, but the mortality rate of influenza was much lower (0.011%) than that of COVID-19. After the early stage, similar increase in the incidence rate with time was observed globally, although the total number of cases differed between regions. The outbreak severe acute respiratory syndrome coronavirus 2 strain in Wuhan had low epidemic intensity and high virulence, but the epidemiological characteristics of severe acute respiratory syndrome coronavirus 2 may not be associated with race, geography, or economic status. Importantly, more effective prevention and control measures and vaccines should be applied for controlling the variants.

摘要

本观察性研究旨在分析中国和全球新冠肺炎疫情爆发和其他地区的数据,以研究在广泛接种疫苗和感染之前,新冠肺炎在获得免疫力之前的流行病学模式。2020 年 1 月至 2021 年 2 月的新冠肺炎相关发病率和死亡率数据来源于中国疾病预防控制中心、湖北省疾病预防控制中心和世界卫生组织。为了比较不同地区随时间变化的增长率或减少率,对病例数进行了对数转换。2020 年 1 月至 2 月,武汉新增确诊病例数大幅增长,但到 2020 年 5 月已降为零。在中国其他地区,下降速度低于武汉,武汉以外地区的死亡率(1.93%)低于武汉(7.68%)。流感趋势与新冠肺炎相似,但流感的死亡率(0.011%)远低于新冠肺炎。在早期阶段,全球范围内观察到发病率随时间的相似增加,尽管不同地区的病例总数有所不同。武汉的新冠病毒株具有低流行强度和高毒力,但新冠病毒的流行病学特征可能与种族、地理位置或经济状况无关。重要的是,应该采取更有效的预防和控制措施和疫苗来控制变异株。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/b246310b11e3/medi-101-e30019-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/bd28db1cec38/medi-101-e30019-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/4545c3a1c1af/medi-101-e30019-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/b4f2deea407e/medi-101-e30019-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/b246310b11e3/medi-101-e30019-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/bd28db1cec38/medi-101-e30019-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/4545c3a1c1af/medi-101-e30019-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/b4f2deea407e/medi-101-e30019-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cea6/9371538/b246310b11e3/medi-101-e30019-g004.jpg

相似文献

1
Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021.基于 2020 年 1 月至 2021 年 2 月收集的数据,分析 SARS-CoV-2 在武汉、中国其他地区和全球的流行病学特征。
Medicine (Baltimore). 2022 Aug 12;101(32):e30019. doi: 10.1097/MD.0000000000030019.
2
The spatial transmission of SARS-CoV-2 in China under the prevention and control measures at the early outbreak.疫情初期防控措施下新型冠状病毒在中国的空间传播。
Arch Public Health. 2021 Jan 13;79(1):8. doi: 10.1186/s13690-021-00529-z.
3
Ecological Study on Differences in COVID-19 Fatality among Wuhan, Rest of Hubei, and Rest of China.武汉、湖北省其他地区和中国其他地区 COVID-19 病死率差异的生态学研究。
J Epidemiol Glob Health. 2021 Mar;11(1):42-45. doi: 10.2991/jegh.k.200902.001. Epub 2020 Sep 10.
4
Early warning and predicting of COVID-19 using zero-inflated negative binomial regression model and negative binomial regression model.使用零膨胀负二项回归模型和负二项回归模型对 COVID-19 进行预警和预测。
BMC Infect Dis. 2024 Sep 19;24(1):1006. doi: 10.1186/s12879-024-09940-7.
5
Risk estimation of the SARS-CoV-2 acute respiratory disease outbreak outside China.中国境外新型冠状病毒急性呼吸道疾病爆发的风险评估
Theor Biol Med Model. 2020 Jun 5;17(1):9. doi: 10.1186/s12976-020-00127-6.
6
Modeling the epidemic dynamics and control of COVID-19 outbreak in China.中国新冠疫情爆发的流行动力学建模与防控
Quant Biol. 2020;8(1):11-19. doi: 10.1007/s40484-020-0199-0. Epub 2020 Mar 11.
7
Influenza versus COVID-19 cases among influenza-like illness patients in travelers from Wuhan to Hong Kong in January 2020.2020 年 1 月,从武汉前往香港的旅行者中流感样疾病患者的流感与 COVID-19 病例。
Int J Infect Dis. 2020 Dec;101:323-325. doi: 10.1016/j.ijid.2020.09.1474. Epub 2020 Oct 1.
8
Epidemiological and Genomic Analysis of SARS-CoV-2 in 10 Patients From a Mid-Sized City Outside of Hubei, China in the Early Phase of the COVID-19 Outbreak.中国湖北以外一个中等规模城市10例新冠肺炎患者早期SARS-CoV-2的流行病学和基因组分析
Front Public Health. 2020 Sep 18;8:567621. doi: 10.3389/fpubh.2020.567621. eCollection 2020.
9
COVID-19 epidemic phases and morbidity in different areas of Chinese mainland, 2020.2020 年中国内地不同地区的 COVID-19 疫情阶段和发病情况。
Front Public Health. 2023 Apr 6;11:1151038. doi: 10.3389/fpubh.2023.1151038. eCollection 2023.
10
Epidemiological characteristics of seasonal influenza under implementation of zero-COVID-19 strategy in China.中国实施“动态清零”策略下季节性流感的流行病学特征。
J Infect Public Health. 2023 Aug;16(8):1158-1166. doi: 10.1016/j.jiph.2023.05.014. Epub 2023 May 16.

引用本文的文献

1
Seroprevalence of SARS-CoV-2 Antibody Before and After Both Vaccination and Natural Infection in China.中国接种疫苗和自然感染前后SARS-CoV-2抗体的血清流行率
Immun Inflamm Dis. 2025 Mar;13(3):e70184. doi: 10.1002/iid3.70184.
2
Sensitivity of major chronic diseases and patients of different ages to the collapse of the healthcare system during the COVID-19 pandemic in China.中国 COVID-19 大流行期间主要慢性疾病和不同年龄患者对医疗体系崩溃的敏感性。
Medicine (Baltimore). 2024 Nov 29;103(48):e40730. doi: 10.1097/MD.0000000000040730.
3
Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.
SARS-CoV-2 变异株的进化与系统发育动态:中国太原市与武汉市的遗传比较研究。
Viruses. 2024 Jun 3;16(6):907. doi: 10.3390/v16060907.
4
Levels of antibodies to SARS-CoV-2 at key time points during the COVID-19 pandemic in China.中国新冠疫情期间关键时间点的新冠病毒抗体水平。
Front Public Health. 2023 Nov 22;11:1271917. doi: 10.3389/fpubh.2023.1271917. eCollection 2023.
5
Pyridine Derivatives as Potential Inhibitors for Coronavirus SARS-CoV-2: A Molecular Docking Study.吡啶衍生物作为新型冠状病毒SARS-CoV-2的潜在抑制剂:分子对接研究
Bioinform Biol Insights. 2023 Jan 6;17:11779322221146651. doi: 10.1177/11779322221146651. eCollection 2023.